

Index

A

- ABCR gene mutations, 26, 32, 108
- Abetalipoproteinemia (Bassen-Kornzweig syndrome), 447, 448
 - electrophysiologic findings in, 27
- Acanthosis nigricans, Alström syndrome-related, 158
- Accessibility, in physician-parent interactions, 89–90
- Accommodation, in myopia, 389, 400
- Achiasmia, 50
- Achromatopsia
 - complete (rod monochromatism), 164
 - electrophysiologic findings in, 30–31
 - congenital (cone monochromatism), 24–25
 - electrophysiologic findings in, 24–25, 30–31, 54
 - incomplete (blue-cone monochromatism), 164–165
 - as nystagmus cause, 155–156
- Acquired immunodeficiency syndrome (AIDS)
 - as ERG electrode contamination source, 9
 - ocular manifestations of, 351, 367–369
- Acute posterior multifocal placoid epitheliopathy (APMPPE), 381–382
- Acute retinal necrosis (ARN) syndrome, 361–363
- Acyclovir, as acute retinal necrosis treatment, 363
- Adenocarcinomas, colonic, 232
- Adenoma sebaceum, 241
- Adrenoleukodystrophy, 27
 - infantile, 446, 447
 - neonatal, 441
 - X-linked, 27, 53
- African Americans
 - incidence of hemoglobinopathies in, 202, 203
 - sickle cell disease in, 201, 203–206
- Aicardi's syndrome, coloboma-like lesions associated with, 421
- Alagille syndrome, 102, 437, 438, 444, 445–446
 - treatment of, 448
- Aland Island eye disease, 35, 51, 399
- Albendazole, 356
- Albinism
 - electrophysiologic findings in, 54
 - visual evoked potentials, 15, 48, 50–51
 - fundal appearance in, 421–423
 - genetic factors in, 51
 - glaucoma associated with, 424
 - nystagmus associated with, 155–156
 - ocular
 - foveal hypoplasia associated with, 421, 422
 - X-linked, carrier state of, 365
 - oculocutaneous (OCA)
 - foveal hypoplasia associated with, 421–422
 - fundal appearance in, 421–422
- Allen dot, 392, 393
- Alloplastic tube shunt implantation, 311
- Alopecia, Vogt-Koyanagi-Harada syndrome-related, 376
- Alport syndrome, 102, 437, 445
 - drusen-like deposits associated with, 124

- Alström syndrome, 153, 158, 429
 cone- and rod-mediated
 electroretinograms in, 31
 as diabetes mellitus risk factor, 444
 hearing loss associated with, 439
 as renal disease risk factor, 444
- Amacrine cells, as scotopic threshold
 response source, 8
- Amaurosis fugax, 222–223
- Amblyopia
 myopia-related, 403
 retinopathy of prematurity-related,
 309–310
 visual evoked potentials in, 54–56
- American Academy of Ophthalmology,
 315–316
- American Academy of Pediatrics,
 315–316
- American Association for Pediatric
 Ophthalmology and Strabismus,
 315–316
- American College of Surgeons
 Oncology Group, 273
- American Committee of Fetus and
 Newborn, 322
- Amsler grid, 103, 120
- Anastomoses, retinal arteriovenous,
 209
- Andersen-Warburg syndrome. *See*
 Norrie's disease
- Anemia, 202, 218
 sickle cell. *See* Sickle cell disease
- Angelman's syndrome, visual evoked
 potentials in, 51
- Angiography, fluorescein
 of drusen, 123
 for Stargardt's disease diagnosis,
 104, 106
- Angioid streaks, 415, 426–427, 437
 sickle cell disease-related, 204, 205
- Angiomas, orbital, 239
- Angiotensin-converting enzyme (ACE),
 as sarcoidosis marker, 354–355
- Aniridia, foveal hypoplasia associated
 with, 422, 424
- Anisometropia, retinopathy of
 prematurity-related, 309–310
- Anterior chamber
 in leukemia, 279
 medulloepithelioma-related cyst or
 mass of, 276
 pars planitis-related inflammation
 of, 352
 sympathetic ophthalmia-related
 inflammation of, 374
- Anticonvulsants
 as color vision loss cause, 165
 visual electrophysiologic effects of,
 46
- Anthelmintic therapy, for
 toxocariasis, 356
- Antinuclear antibodies (ANA), 357
- Aortitis syndrome, 216
- APC gene mutations, 233
- Apert syndrome, 43
- Aplasia, vitreoretinal, 415, 427
- Apnea, as retinopathy of prematurity
 risk factor, 293–294
- Apraxia, oculomotor, 156
- Arden ratio/index, 12
 in Best's disease, 31–32, 112, 113,
 119
- Arteriosclerosis, as hypertensive
 retinopathy cause, 210
- Arteriovenous shunts, 221
- Arteritis, Kawasaki's disease-related,
 221
- Asthenopia, 397
- Astigmatism, retinopathy of
 prematurity-related, 317
- Astrocytomas, retinal, 241–243
- Ataxia
 cerebellar, visual evoked potentials
 in, 45–46
 Friedreich's, visual evoked
 potentials in, 45–46
 spinocerebellar, type 7, 167
 Usher syndrome-related, 157
- Ataxin 7, 167
- Atropine, as myopia treatment, 401
- Awareness, in physician-parent
 interactions, 89
- B
- Bardet-Biedl syndrome, 27–28, 153,
 158–159, 430, 432, 442
 renal disease associated with, 444
- Barkan's-like membrane, 311
- Bassen-Kornzweig syndrome. *See*
 Abetalipoproteinemia
- Batten disease. *See* Neuronal ceroid-
 lipofuscinosis, infantile
- "Bear tracks," 230, 232, 243
- Benign concentric annular macular
 dystrophy, 116, 118
- Berson color vision test, 31, 164

- Best's disease (vitelliform dystrophy),
108–115, 148
carriers of, 110
as central vision impairment
cause, 103
differentiated from pattern
dystrophies, 119
electrophysiologic findings in,
31–32, 119
genetic factors in, 111–112
lipofuscin deposits in, 109, 110,
111, 112, 114, 115
pathophysiology of, 112, 114–115
reticular pigmentation associated
with, 119, 120
- Bifocals, for myopic patients, 402
- Bitot's spots, 378, 379
- "Black sunbursts," 203, 204
- Blindness. *See also* Visual
loss/impairment
cortical, normal flash visual
evoked potentials in, 51–52
hysterical, 430
legal, 141
myopia-related, 389, 394
retinitis pigmentosa-related,
153
Stargardt's disease-related, 103
Norrie's disease-related, 217
referrals and information resources
regarding, 92
retinitis pigmentosa-related, 141,
153
retinopathy of prematurity-related,
285, 286
- Bloch-Sulzberger syndrome. *See*
Incontinentia pigmenti
- Blood transfusions, as retinopathy of
prematurity risk factor, 294
- Blunt trauma, of the head, child abuse-
related, 212
- Blurred vision, pars planitis-related,
350, 352
- Bone marrow transplantation
as mucopolidiosis I treatment,
441–442
as mucopolysaccharidoses
treatment, 448
as osteopetrosis treatment, 43
- Bone tumors, retinoblastoma-related,
268, 269
- Brachydactyly, Bardet-Biedl syndrome-
related, 158–159
- British Association for Perinatal
Medicine, 315
- Bruch's membrane
breaks in. *See also* Angioid streaks
in myopic eyes, 394, 395
drusen-related abnormalities of,
123–124
Sorsby's fundus dystrophy-related
lipid deposits in, 126
- Bruits, orbital, 221
- Bull's-eye maculopathy, 415, 430–432
Alström syndrome-related, 158
cone dystrophy-related, 162
- Burian-Allen contact lens electrode, 10
- Butterfly pattern dystrophy, 116, 117
- C
- Calcification
intracranial, toxoplasmosis-related,
358
periventricular, lymphocytic
choriomeningitis virus-related,
361
retinal astrocytoma-related, 242,
243
retinoblastoma-related, 255, 256,
268
sclerochoroidal, 239
uveal melanoma-related, 275
- Cancer
pigmentary retinopathy associated
with, 449
referrals and information resources
regarding, 91
- Canthaxanthine, toxicity of, 129, 351
- Carbamazepine, as color vision loss
cause, 165
- Carbonic anhydrase inhibitors, as
cystoid macular edema treatment,
149
- Carboplatin, as retinoblastoma
treatment, 271, 272, 273
- Cardiomyopathy, Leber's congenital
amaurosis-related, 155
- Cataracts
congenital rubella syndrome-
related, 439
electrophysiologic findings in, 39
erosive vitreoretinopathy-related,
187
hereditary snowflake vitreoretinal
degeneration of Hirose-related,
194, 195

- Cataracts (*Continued*)
 incontinentia pigmenti-related, 213
 juvenile rheumatoid arthritis-related, 357, 358
 Leber's congenital amaurosis-related, 155
 leukocoria associated with, 314
 medulloepithelioma-related, 276
 pars planitis-related, 353
 retinitis pigmentosa-related, 137
 treatment of, 149
 in retinopathy of prematurity patients, 294–295
 siderosis-related, 379, 380
 Stickler syndrome-related, 186
- Cats
 as *Toxocara catis* host, 355, 434
 as toxoplasmosis carrier, 361, 434
- CD4 lymphocyte count, 368
- Cellulitis, orbital, 253
- Central areolar pigment epitheliopathy, 124
- Central nervous system disorders,
 hypomelanosis of Ito-related, 215
- Central retinal artery occlusion, cherry-red spots associated with, 416
- Central retinal vein, carotid cavernous fistula-related occlusion of, 221
- Central vision impairment
 North Carolina macular dystrophy-related, 124–125
 Stargardt's disease-related, 103, 107
- Cerebellar vermis, hypoplasia of, 156
- Cerebral palsy
 perinatal hypoxia-related, 52
 referrals and information resources regarding, 91–92
- Cerebrospinal fluid analysis (CSF), for syphilis diagnosis, 365–366
- Chalcosis, 351, 379, 381
- CHARGE association, 419
 referrals and information resources regarding, 92
- Chediak-Higashi syndrome, 422
- Chemoreduction, as retinoblastoma treatment, 271
- Chemotherapy
 for retinoblastoma, 271–272
 visual electrophysiologic effects of, 47
- Cherry-red spots, 413, 414, 416
- Chest compression, as Purtscher's retinopathy cause, 212, 213
- Chiasmal abnormalities, visual evoked potentials in, 48–51
 crossed asymmetry of, 48, 49, 50–51
- Child abuse
 as Purtscher's retinopathy cause, 213
 as shaken baby syndrome cause, 212
- Children's Cancer Group (CCG), 257
- Children's Oncology Group (COG), 257
 Retinoblastoma Steering Committee, 273
- Chlamydia* infections, 434
- Chlorambucil
 as cystoid macular edema treatment, 353
 as sympathetic ophthalmia treatment, 376
- Chloroquine, 102
 visual electrophysiologic effects of, 47
- Chlorpromazine, as rod dysfunction cause, 25
- Choriocapillaris lobules,
 hyperpigmentation near, 119, 120
- Choriomeningitis, lymphocytic, 419, 421
- Chorioretinal atrophy, 396–397, 434, 435, 436
- Chorioretinitis, 434
 Cogan syndrome-related, 442
 incontinentia pigmenti-related, 213
 lymphocytic choriomeningitis virus-related, 361
- Choristomatous malformation, of the optic nerve, 255
- Choroid
 in albinism, 423
 colobomas of, 239
 dark/masked, Stargardt's disease-related, 104, 108, 118
 infarctions of, 210, 211, 215
 melanoma of, 227–228, 273, 274, 275
 neurilemmoma of, 243
 neurofibroma of, 243
 nevi of, 226–228
 misdiagnosed as melanocytoma, 229
 osteoma of, 237–240
 sarcoidosis-related lesions of, 354, 355

- Choroid (*Continued*)
 toxoplasmosis-related
 inflammation of, 359
- Choroidal neovascular membranes (CNVM), 227
- Choroideremia, 96, 436
 carrier state of, 146
- Choroiditis, histoplasmosis-related, 371
- Chronic illness, referrals and information resources regarding, 92
- Chronic obstructive pulmonary disease, 419
- Chronic progressive external ophthalmoplegia, 30
- CHRPE. *See* Congenital hypertrophy of the retinal pigment epithelium
- Churg-Strauss syndrome (allergic granulomatosis), 202, 216
- Ciliary body, melanoma of, 274, 275
- Ciliary spasms, in myopic eyes, 390
- Ciliodestructive procedures, as retinopathy of prematurity-related glaucoma treatment, 311
- Cilioretinal artery occlusion, cherry-red spots associated with, 416
- Circadian rhythm, effect on electroretinography findings, 10
- CLAMP (Contact Lens and Myopia Progression) study, 402–403
- Clarity, in physician-parent interactions, 89
- Cleft palate, Stickler syndrome-related, 184, 398–399
- Closed-circuit television, 18–19
- Coats' disease, 202, 206–208
 anomalous retinal blood vessels in, 416–417
 staging classification of, 207–208
- Cockayne syndrome, 437, 444
 hearing loss associated with, 439
- COG. *See* Children's Oncology Group
- Cogan syndrome, 442, 449
- COL2A1 gene mutations, 37
- Collaborative Ocular Melanoma Study (COMS), 275
- Collagen, as vitreous component, 390
- Collagen II, Stickler syndrome-related abnormalities in, 184
- College of Ophthalmologists, 315
- Colobomas
 choroid, 239
 of the eyelids, 239
 of the iris, 239
 macular, 414, 419–421
 nevus sebaceous of Jadassohn-related, 239
 of the optic disc, 239
 retinal, systemic disorders-associated, 437
- Colon, adenocarcinoma of, 232
- Color blindness. *See* Dyschromatopsias
- Color vision, retinitis pigmentosa-related loss of, 149
- Color vision testing, 163
- Compassion, in physician-parent interactions, 89
- Computed tomography (CT), of retinoblastoma, 267–268
- COMS (Collaborative Ocular Melanoma Study), 275
- Cone dystrophies, 135–136, 162–163
 a-wave amplitude in, 7
 progressive, flash electroretinogram in, 24–25
- Cone monochromatism, 24–25
- Cone-rod dystrophies, autosomal dominant, 162–163
- Cones, electroretinography of, 4, 5–6, 22, 23
- Congenital heart disease, incidence of, 247
- Congenital hereditary endothelial dystrophy (CHED), 39, 40
- Congenital hypertrophy of the retinal pigment epithelium (CHRPE), 230–234
 inherited gastrointestinal polyposis associated with, 232–234
- Congenital rubella syndrome, 351, 363–365, 428–429, 432–433, 439
- Congenital vascular loops, 202, 222–223
- Connective tissue disorders, myopia associated with, 434
- Consideration, in physician-parent interactions, 88
- Contact lens, for myopic patients, 402–403
- Contact lens electrodes, 9, 10, 21
- Copper-containing foreign bodies, 381
- Corneal crystals, 445
- Corneal dystrophy, as retinopathy of prematurity-related glaucoma risk factor, 311

- Corneal haze/opacity
 electrophysiologic findings in,
 38–39
 fucosidrosis-related, 418
 photorefractive keratectomy-
 related, 403
- Corneal pannus, hypomelanosis of Ito-
 related, 215
- Cornea verticillata, 418
- Corticosteroids
 as acute posterior multifocal
 placoid epitheliopathy (APMPPE)
 treatment, 382
 as acute retinal necrosis treatment,
 363
 as Cogan syndrome treatment, 442
 contraindication in juvenile
 rheumatoid arthritis, 357–358
 as pars planitis treatment, 353
 as retinopathy of prematurity-
 related glaucoma treatment, 311
 as sarcoidosis treatment, 355
 as sympathetic ophthalmia
 treatment, 374, 376
 as Vogt-Koyanagi-Harada syndrome
 treatment, 376–377
- “Cotton- wool spots,” 204, 210
 AIDS-related, 367
 Purtscher’s retinopathy-related,
 212, 213
 Takayasu’s arteritis-related, 216
- Craniofacial dysostosis,
 electrophysiologic findings in,
 43–44
- Craniopharyngiomas,
 electrophysiologic findings in, 48–49,
 54
- Creutzfeldt-Jakob disease, 9
- Crohn’s disease, pattern dystrophies-
 related, 119
- Crouzon syndrome, 43
- CRYO-ROP. *See* Multicenter Trial of
 Cryotherapy for Retinopathy of
 Prematurity (CRYO-ROP)
- Cryotherapy
 for intratentorial hemangiomas,
 209
 for retinoblastoma, 271
 for retinopathy of prematurity, 285,
 292. *See also* Multicenter Trial
 of Cryotherapy for Retinopathy
 of Prematurity (CRYO-ROP)
 as myopia risk factor, 398
 for sickle retinopathy, 206
 for toxocariasis, 356
- Crystalline retinal dystrophies, 128–129
- Cyclomydril eye drops, 317
- Cyclopentolate, 317
- Cycloplegic agents
 as retinopathy of prematurity-
 related glaucoma treatment, 311
 as syphilitic uveitis treatment, 367
 as toxocariasis treatment, 356
- Cyclosporin A, 358
- Cyclosporine, 353
 as retinoblastoma treatment, 273
 as sympathetic ophthalmia
 treatment, 376
 as Vogt-Koyanagi-Harada syndrome
 treatment, 377
- Cystinosis, 444–445
 differentiated from crystalline
 retinal dystrophy, 129
 treatment of, 448
- Cysts, von Hippel-Lindau syndrome-
 related, 208–209
- Cytomegalovirus infections, 432, 433
 in AIDS patients, 367–369
- D
- Dalen-Fuchs nodules, 374
- Darier’s disease, 436, 437
- Dark adaptometry, 102, 141, 145
- Deafness. *See also* Hearing loss
 Alström syndrome-related, 158
 Leber’s congenital amaurosis-
 related, 155
 Norrie’s disease-related, 314
 referrals and information resources
 regarding, 92
 retinopathies associated with,
 437–442
- Dermatological disorders, retinal
 disease-associated, 436, 437
- Desferoxamine, toxicity of
 adverse ocular effects of, 102, 432
 as retinitis pigmentosa mimic,
 149–150
 visual electrophysiologic effects of,
 47
- Deuteranomaly, 163–164
- Deuteranopia, 164
- D-15 color vision test, 163
- Diabetes mellitus
 Alström syndrome-related, 158,
 444

- Diabetes mellitus (*Continued*)
 as maternally inherited diabetes
 and deafness (MIDD) component,
 119
 retinal neovascularization in, 418
 retinopathy of, 202, 210
- Diagnosis, of child's disability, parental
 response to, 82–95
 grieving process, 82–95
 physician's role in, 88–91
 resources and referrals for, 91–95
- Dichomats, 163
- Diffuse unilateral subacute
 neuroretinitis (DUSN), 165, 351,
 369–371
- Diktyomas (medulloepitheliomas),
 276–278
- Dogs, as *Toxocara canis* hosts, 355
- Dominant progressive foveal dystrophy,
 124
- Down syndrome (trisomy 21), 421
- Drug toxicity. *See also names of
 specific drugs*
 electrophysiologic findings in,
 46–47
- Drusen, 101, 121–124
 as central vision impairment
 cause, 103
 choroidal nevus-related, 227, 228
 cuticular/basal laminar, 121, 122,
 123, 124
 histopathology of, 123–124
 natural history of, 123
 of the optic nerve, 446
 Sorsby's fundus dystrophy-related,
 126
- Dwarfism
 Kneist dysplasia-related, 399
 short-limbed, Jeune's syndrome-
 related, 442, 444
 thoracic, 442
- Dyschromatopsias (color blindness),
 163–165
 autosomal recessive incomplete,
 visual evoked potentials in, 41
 congenital, 135–136
 X-linked, visual evoked potentials
 in, 41
- Dysplasia
 asphyxiating thoracic (Jeune's
 syndrome), 442
 epiphyseal, Stickler syndrome-
 related, 183, 185
- Kneist, 399
 retinal, retinal detachment
 associated with, 424
 vitreoretinal, 415, 427
- Dystrophies
 Becker muscular,
 electroretinographic findings in,
 35
 cone, 135–136, 162–163
 a-wave amplitude in, 7
 progressive, flash
 electroretinogram in, 24–25
 crystalline retinal, 128–129
- Duchenne's muscular,
 electroretinographic findings in,
 35–36
- fascioscapulohumeral, 202,
 217–218
- macular
 fenestrated sheen, 127–128
 North Carolina, 32, 124–126,
 419, 421
 slowly progressive, 118
- Malattia Levetinese and Doyne
 honeycomb retinal, 124
- myotonic, 447
- pattern, 115–120
 benign concentric annular
 macular, 116, 118
 butterfly, 116, 117
 as central vision impairment
 cause, 103
 Mesker's macroreticular,
 115–116
 peculiar foveomacular, 116,
 117
 Sjögren's reticular dystrophy,
 115
- rod/cone
 Bardet-Biedl syndrome-related,
 158
 progressive. *See Retinitis
 pigmentosa*
 scapulooperoneal, 218
 Sorsby's fundus, 126–127
 vitelliform. *See Best's disease*
- E
- Eales' disease, 202, 213
- Early Treatment for Retinopathy of
 Prematurity study, 333
- Ectopia, retinopathy of prematurity-
 related, 302

- Edema, retinal, 416
 cherry-red spots associated with, 416
 cystoid macular, 139
 autosomal dominant
 neovascular inflammatory vitreoretinopathy-related, 198
 autosomal dominant vitreoretinopathy-related, 196, 197
 differentiated from Goldmann-Favre syndrome, 187–188
 juvenile rheumatoid arthritis-related, 357
 pars planitis-related, 352, 353–354
 treatment of, 149
 incontinentia pigmenti-related, 213
 macular
 diabetic, 210
 Goodpasture's syndrome-related, 215
- EFEMP1 gene mutations, 124
- E-Ferol, 322
- Ehlers-Danlos VI syndrome, 426
- Electrodiagnostic tests
 advantages of, 1–2
 functional sensitivity of, 2
 graphic depiction of results of, 2
- Electro-oculography (EOG), 12
 amplitude of, 12
 in Best's disease, 32, 111, 112, 113, 148
 definition of, 1
 diagnostic applications of, 38
 electrodes in, 12
 in Goldmann Favre syndrome, 36
 in inherited ocular disease, 102
 International Society for Clinical Electrophysiology of Vision standards for, 12
 technique for, 12
- Electrophysiology, pediatric visual, 1-3.
 See also Electro-oculography (EOG); Electroretinography (ERG); Visual evoked potentials (VEPs)
 future of, 59
- Electroretinography (ERG)
 a-waves in
 evaluation of, 22
 maturation of, 24
 blue-cone, 31
 b-waves in
 effect of fundal pigmentation on, 10
 evaluation of, 22
 in hereditary vitreoretinal degeneration of Hirose, 195
 maturation of, 24
 in combination with visual evoked potentials, 2, 21–23
 GOS pediatric protocol for, 21–23
 in infants with nystagmus, 54
 cone-mediated, 4, 5–6
 a-waves in, 5–6
 b-waves in, 5–6
 elicitation of, 22, 23
 in congenital rubella, 429
 in congenital stationary night blindness, 156, 160–161
 c-waves in, 8
 definition of, 1
 d-waves in, 8
 effect of anesthesia on, 21
 flash (FERG), 3
 a-waves in, 5, 6–7
 b-waves in, 5, 7
 diagnostic applications of, 24–37
 in Goldmann Favre syndrome, 36, 37
 in hydrocephalus, 52
 in intraocular hemorrhage, 39–40
 in neuronal ceroid-lipofuscinosis, 36
 in ocular opacities, 38–40
 processes and components of, 5–8
 skin electrode recordings in, 9
 flicker, 8
 in Goldmann-Favre syndrome, 36, 37, 188
 in gyrate atrophy, 167
 in infants, 148
 in inherited ocular disease, 102
 International Society for Clinical Electrophysiology of Vision (ISCEV) standards for, 19–23
 for dark-adapted responses, 20
 for light-adapted responses, 20
 for recording in young children, 21–23

- Electroretinography (ERG) (*Continued*)
- in Leber's congenital amaurosis, 156
 - maturation of, 24
 - multifocal (mfERG), 3–4
 - "negative," 32–36
 - clinical conditions associated with, 32–36
 - definition of, 32–33
 - Schubert-Bornschein, 32–33
 - in normal patients, 146
 - origins of, 4–5, 4–9
 - paired-flash, 5
 - pattern (PERG), 3, 8–9
 - diagnostic applications of, 37
 - GOS pediatric protocol for, 23
 - in maculopathies, 40–41
 - in rod dysfunction, 25
 - signal averaging of, 11
 - physical factors affecting, 10
 - physiological factors affecting, 10
 - recording methods in, 9–11
 - amplification, 10–11
 - averaging, 11
 - electrodes, 9–10, 21
 - in retinitis pigmentosa, 136, 145–148, 151
 - rod-mediated, 4, 6
 - b-waves in, 6
 - elicitation of, 22, 23
 - sinusoidal, 8
 - scotopic threshold response (STR)
 - in, 8
 - in siderosis, 379, 380, 381
 - signal averaging of, 11
 - in X-linked juvenile retinoschisis, 190
- Embryotoxon, posterior, 446
- Encephaloceles, 399, 427
- Endarterectomy, as Takayasu's arteritis treatment, 216
- Enhanced S-cone sensitivity (ESCS) syndrome, 36–37, 166
- Enterocolitis, necrotizing, 322
- Enucleation
 - as intraocular retinoblastoma treatment, 271, 272
 - as medulloepithelioma treatment, 277, 278
- EOG. *See* Electro-oculography (EOG)
- Epiphyseal dysplasia, Stickler syndrome-related, 183, 185
- Epiretinal membranes
 - pars planitis-related, 353–354
 - toxocariasis-related, 356
- Episcleritis, 215
- Epitheliopathy, acute posterior multifocal placoid pigment (APMPPE), 381–382
- ERG. *See* Electroretinography (ERG)
- Erosive retinopathy, 37
- Esotropia, 255
 - accommodative, 397
- Etanercept, 358
- Ethambutol, visual electrophysiologic effects of, 47
- Etoposide, as retinoblastoma treatment, 271, 272, 273
- Exophthalmos, carotid cavernous fistula-related, 221
- Exudates, subretinal, 206, 207, 208, 209
- Eyelids, colobomas of, 239
- F
- Fabry's disease
 - petechial lesions associated with, 437
 - retinal vascular tortuosity associated with, 416, 418
 - treatment of, 419
- Facial anomalies
 - retinal disorders associated with, 437, 444
 - Stickler syndrome-related, 182–183, 184, 398–399
- Familial adenomatous polyposis, 232, 233
- Familial exudative vitreoretinopathy (FEVR), 179, 191–194, 313, 314, 424
- Familial retinal arteriolar tortuosity, 416–417
- Fascioscapulohumeral dystrophy, 202, 217–218
- Fenestrated sheen macular dystrophy, 127–128
- Fetal hydrops, 316
- Fibroblast growth factor receptor gene mutations, 43
- "Fishtail lesions," 233
- Fistulas, carotid cavernous, 202, 221
- Fleck retina of Kandori, 161
- Flecks, 101
 - Stargardt's disease-related, 103, 105
- Flies, ocular infestations with (ophthalmomyiasis), 351, 369

- "Floaters"
 definition of, 178
 in myopic eyes, 390–391
 pars planitis-related, 350, 352
 toxoplasmosis-related, 359
- Flynn-Aird syndrome, 437, 439, 447
- Folinic acid, as toxoplasmosis
 treatment, 359, 360–361
- Foreign bodies, intraocular retained
 metallic, 379–381
- Foscarnet, as cytomegalovirus retinitis
 treatment, 368–369
- Fovea
 hypoplasia of, 51, 414, 421–424
 Stargardt's disease-related
 dysfunction of, 32
- Foveal avascular zone, in cicatricial
 retinopathy of prematurity, 310
- Foveal schisis, 189
- Franceschetti, oculodigital sign of, 155
- Freckles, choroidal, 226–227
- Fuch's spots, 395–396
- Fucosidosis, 418
- Fundus
 in anemia, 218
 in Goldmann-Favre syndrome, 187,
 188
 in hypertensive retinopathy, 210
 in hyperviscosity syndromes, 220
 in myopic eyes, 388, 391–397
 ophthalmoscopic appearance in
 retinal diseases, 413–436
 angioid streaks, 415, 426–427
 bull's-eye maculopathy, 415,
 430–432
 cherry-red spots, 413, 414, 416
 congenital retinal disease, 415,
 432–434
 foveal hypoplasia, 414,
 421–424
 "fried-egg" appearance, 31–32
 geographic pigmentary
 disturbances, 415, 434–436
 leukocoria, 415, 436
 macular colobomas, 414,
 419–421
 "peau d'orange" appearance,
 437, 441
 retinal detachment, 414,
 424–426
 "salt-and-pepper" mottling,
 363–364, 365, 366, 415,
 427–429
 "scrambled-egg" appearance, 32
 vascular tortuosity, 414,
 416–419
 vitreoretinal dysplasia or
 aplasia, 415, 427
- pigmentation of
 effect on electroretinogram, 10
 geographic disturbances of,
 415, 434–436
 in retinitis pigmentosa, 135,
 137, 138, 139–140
 retinitis pigmentosa-related
 abnormalities of, 135, 137, 138,
 139–140, 153, 154
 bone-spicule
 hyperpigmentation, 137,
 138, 139–140
 in retinoblastoma, 253, 254, 255
 "salt-and-pepper" mottling of, 415,
 427–429
 rubella-related, 363–364, 365
 syphilis-related, 365, 366
 in shaken baby syndrome, 212
 in sickle cell disease, 203–204
- Fundus albipunctatus (FAP), 139–140,
 161
- Fundus flavimaculatus, 32, 105, 107,
 120, 430
- Fundus pulverulentus, 115, 116
- G
- Ganciclovir, as cytomegalovirus
 retinitis treatment, 368–369
- Ganzfeld effect, 40
- Gardner's syndrome, 232
- Geographic pigmentary disturbances,
 415, 434–436
- German measles. *See* Rubella
- Gestational age, low, as retinopathy of
 prematurity risk factor, 285–286, 289,
 294, 315
- Glaucoma
 albinism-related, 424
 aniridia-related, 424
 carotid cavernous fistula-related,
 221
 juvenile rheumatoid arthritis-
 related, 357
 medulloepithelioma-related, 276
 pars planitis-related, 353
 retinoblastoma-related, 253, 254
 retinopathy of prematurity-related,
 310–311, 317

- Glaucoma (*Continued*)
 siderosis-related, 379
 Stickler syndrome-related, 182
- Gliomas
 chiasmal, 48
 electrophysiologic findings in, 44, 54
 of the optic nerve,
 electrophysiologic findings in, 44
- Goldmann-Favre syndrome, 166, 179, 187–188
 electrophysiologic findings in, 36–37
- Goldmann visual fields, in rhodopsin-associated retinitis pigmentosa, 143
- Goltz syndrome, 419, 437
- Goodpasture's syndrome, 202, 215–216
- Gorgonia flabellum*, 204
- G-protein, role in phototransduction, 6–7
- Granulomas
 choroidal, toxocariasis-related, 355, 356
 noncaseating, sarcoidosis-related, 354
- Granulomatosis, allergic (Churg-Strauss syndrome), 202, 216
- Grass PS22 photic stimulator, 22–23
- Growth hormone deficiency, 444
- Guanylate cyclase 2D gene mutations, 162–163
- Gyrate atrophy, 26–27, 96, 166–167, 434, 435, 436, 447–448
 in myopic eyes, 399
- H**
- HAART (highly-active anti-retroviral therapy), 369
- Hallervorden-Spatz syndrome, 430, 447
- Haltia-Santavuori syndrome, 159, 430, 446
- Hamartomas
 astrocytic, 241–243
 differentiated from
 retinoblastoma, 254
 neurofibromatosis-related, 243
 tuberous sclerosis-related, 241–243, 254
 combined, of the retinal pigment epithelium and retina, 235–237
 congenital hypertrophy of the retinal pigment epithelium-related, 232–233
 nonvascular, 226–245
 choroidal nevus, 226–228
 choroidal osteoma, 237–240
 CHRPE lesions, 232–234
 combined hamartoma of the retinal pigment epithelium and retina, 235–237
 congenital hyperplasia of the retinal pigment epithelium, 234–235
 congenital hypertrophy of the retinal pigment epithelium, 230–232
 gastrointestinal polyposis, 232–234
 melanocytoma (magnocellular nevus), 229–230
 neurofibromatosis, 243
 tuberous sclerosis, 241–243
 of the retinal pigment epithelium, 274
- Hardy Rand Ritler color vision testing plates, 163
- Head trauma, as shaken baby syndrome cause, 212
- Hearing loss
 Alström syndrome-related, 429
 Cockayne syndrome-related, 441
 Cogan syndrome-related, 449
 congenital rubella-related, 429, 439
 congenital syphilis-related, 429
 fascioscapulohumeral dystrophy-related, 217–218
 Norrie's disease-related, 217, 427
 retinitis pigmentosa-related, 157
 Stickler syndrome-related, 184, 398–399
 Usher syndrome-related, 28, 157
 Vogt-Koyanagi-Harada syndrome-related, 376
- Hemangioblastomas, infratentorial, 208, 209
- Hemangiomas
 capillary
 anomalous retinal blood vessels in, 416–417
 von Hippel disease-related, 208, 242–243
 cavernous, 209, 416–418
 choroidal, 209
 facial, 237
 racemose, 416–417

- Hemianopia, visual evoked potentials
in, 16, 17
- Hemoglobin C, 201, 203
- Hemoglobin S, 201, 203
- Hemoglobin SC, 204
- Hemorrhage
intraocular, electrophysiologic
findings in, 39–40
macular, in myopic eyes, 394–396
retinal
acute retinal necrosis-related,
362
anemia-related, 218
incontinentia pigmenti-related,
213
leukemia-related, 219,
278–279
in myopic eyes, 394–396
“salmon patch,” 203, 204
subarachnoid, Terson’s syndrome-
related, 210–211
subdural, 211
vitreous
autosomal dominant
neovascular inflammatory
vitreoretinopathy-related,
198
autosomal dominant
vitreoretinopathology-
related, 197
congenital vascular loops-
related, 222–223
differentiated from Norrie’s
disease, 424
juvenile X-linked retinoschisis-
related, 191
pars planitis-related, 353–354
retinoblastoma-related, 252,
253
shaken baby syndrome-related,
212
sickle cell disease-related, 204,
206
Takayasu’s arteritis-related,
216
Terson’s syndrome-related,
210–211
X-linked juvenile retinoschisis-
related, 166
- Hepatitis B virus, as ERG electrode
contaminant, 9
- Hereditary progressive arthro-
ophthalmopathy, 182
- Hereditary snowflake vitreoretinal
degeneration of Hirose, 179, 194–196
- Heritable disorders, of retinal pigment
epithelium, Bruch’s membrane, and
the choriocapillaris, 96–134
bilateral lesions of the posterior
pole
Best’s disease (vitelliform
dystrophy), 108–115
crystalline retinal dystrophies,
128–129
drusen, 121–124
fenestrated sheen macular
dystrophy, 127–128
general approach to, 100–103
North Carolina macular
dystrophy, 124–126
pattern dystrophies, 115–120
Sorsby’s fundus dystrophy,
126–127
Stargardt’s disease, 103–108
ophthalmoscopically-based
nomenclature for, 97–98, 99–100
- Hermansky-Pudlak syndrome, 422
- Herpes simplex virus, as retinitis cause,
369
- Herpes virus infections, 432
- Herpes zoster virus, as retinitis cause,
369
- Heterochromia iridis, 442
hypomelanosis of Ito-related, 215
- Highly-active anti-retroviral therapy
(HAART), 369
- High-protein diet, as color vision loss
cause, 165
- Hip dislocation, congenital, incidence
of, 247
- Histoplasma capsulatum*, as
histoplasmosis cause, 371
- Histoplasmosis, presumed ocular
syndrome of (POHS), 351, 371–373
- HLA-DR2 suballele-DR1501, 350
- Homocystinuria, 416, 448
corneal opacities associated with,
38
- HTLV-1 (human T-lymphotropic virus),
351, 361
- Human immunodeficiency virus (HIV)
infection, 433, 434
- Human papilloma virus (HPV), as
retinoblastoma risk factor, 257–258
- Human T-lymphotropic virus (HTLV-1),
351, 361

- Hunter's syndrome, 29
- Hurler syndrome, 29
- Hutchinson's teeth, 365
- Hyaluronic acid, as vitreous component, 178, 390
- Hydrocephalus
 - lymphocytic choriomeningitis virus-related, 361
 - referrals and information resources regarding, 92–93
 - toxoplasmosis-related, 358
 - visual evoked potentials in, 51, 52–53
- Hypercalciuria, idiopathic, 444
- Hypercarbia, as retinopathy of prematurity risk factor, 293
- Hyperornithinemia, 436, 447–448
- Hyperpigmentation, congenital
 - hypertrophy of the retinal pigment epithelium-related, 230, 231
- Hypertension, ocular, Stickler syndrome-related, 182
- Hyperviscosity syndromes, 202, 219–220
 - branch retinal vein occlusions associated with, 222
- Hyphema
 - congenital vascular loops-related, 222–223
 - retinoblastoma-related, 252, 253
- Hypocarbica, as retinopathy of prematurity risk factor, 293
- Hypogonadism
 - Alström syndrome-related, 158
 - Bardet-Biedl syndrome-related, 432, 442, 443
- Hypomelanosis of Ito, 202, 215
- Hypopigmentation
 - congenital hypertrophy of the retinal pigment epithelium-related, 230, 231
 - viteligo-related, 437
 - Vogt-Koyanagi-Harada syndrome-related, 437
- Hypoxemia, as retinopathy of prematurity risk factor, 293
- Hypoxia
 - perinatal, visual evoked potentials in, 52
 - as retinopathy of prematurity risk factor, 289–293
 - sickle cell disease-related, 203
- I
- Ichthyosis, 436, 437
- Immunocompetent patients. *See also* Acquired immunodeficiency syndrome (AIDS); Human immunodeficiency virus (HIV) infection
 - acute retinal necrosis in, 361–363
- Immunoglobulin G
 - deposition in the basement membrane, 215
 - as toxoplasmosis marker, 359
- Immunoglobulin M, as toxoplasmosis marker, 359
- Immunosuppressive therapy, for Goldmann-Favre syndrome, 188
- Incontinentia pigmenti, 202, 213–215, 419, 427, 437
 - treatment of, 419
 - vitreoretinal dysplasia associated with, 427
- Indomethacin
 - as retinopathy of prematurity risk factor, 294
 - visual electrophysiologic effects of, 46
- Infants, electroretinography testing in, 148
- Infarction, choroidal, 210, 211, 215
- Infectious diseases, of the retina and vitreous
 - acquired immunodeficiency syndrome (AIDS), 351, 367–369
 - histoplasmosis, 351, 371–373
 - lymphocytic choriomeningitis virus (LCMV) chorioretinitis, 361
 - syphilis, 351, 365–367
 - toxocariasis, 351, 355–357
 - toxoplasmosis, 351, 358–361
- Inflammatory diseases, of the retina and vitreous
 - differentiated from inherited disease, 102
 - pars planitis, 350, 351, 352–354
 - sarcoidosis, 351, 354–355
- International Classification of Retinopathy of Prematurity (ICROP), 295–302, 316
 - extent ("clock hours") parameter of, 295, 296, 299
 - location zone parameter of, 295–296

- International Classification of Retinopathy of Prematurity (ICROP) (*Continued*)
 severity (stages) parameter of, 295, 296–302, 303–309, 418–419
- International Federation of Clinical Neurophysiology, 2
- International Society for Clinical Electrophysiology of Vision (ISCEV), 2, 8–9
 standards of, 145
 for electro-oculography, 12, 19–20
 for electroretinography, 19–23
 for visual evoked potentials, 19–20
- International Symposium on Retinoblastoma, Franceschetti Lecture, 271
- Intracranial pressure (ICP), in hydrocephalus, 52–53
- Intraocular pressure (IOP), in myopic eyes, 389, 403
- Iridescent spots, 203–204
- Iridocyclectomy, as medulloepithelioma treatment, 278
- Iridocyclitis
 antiretroviral therapy-related, 369
 corticosteroid treatment of, 355
- Iris
 atrophy of, sickle cell disease-related, 204, 205
 coloboma of
 hypomelanosis of Ito-related, 215
 nevus sebaceous of Jadassohn-related, 239
 hypoplasia of, aniridia-related, 422, 423
 melanoma of, 274
- Iris transillumination defects, 421, 422
- Iron-containing foreign bodies, 379–381
- Ischemia, Takayasu's arteritis-related, 216
- Ishihara color vision testing plates, 163, 164
- J
- Jansky-Bielschowsky syndrome, 159, 430, 447
- Jaundice
 neonatal, 445
 toxoplasmosis-related, 358
- Jeune's syndrome, 442
- Joints, Stickler syndrome-related degeneration of, 182–183
- Joubert syndrome, 447
 electrophysiologic findings in, 28–29
 as Leber's congenital amaurosis mimic, 156
- K
- Kawasaki's disease, 202, 220–221
- Kayser-Fleischer rings, 381
- Kearns-Sayre syndrome, 30, 442, 447
- Keratotomy, photorefractive, 403
- Keratitis, interstitial
 Cogan syndrome-related, 442
 congenital syphilis-related, 429
- Keratoconus, Leber's congenital amaurosis-related, 155
- Keratopathy, band, 357
- Keratorefractive surgery, 403
- Kidney disease. *See* Renal disease
- Kneist dysplasia, 399
- Knobloch syndrome, 399
- Kuf's disease, electrophysiologic findings in, 36
- L
- "Lacquer cracks," 394, 395
- Lactic acidosis and stroke-like episodes (MELAS), 30
- Larva migrans, visceral, 355–356
- Laser in situ keratomileusis (LASIK), 403
- Laser Retinopathy of Prematurity (ROP) Study, 333
- Laser therapy. *See also* Photocoagulation
 for choroidal neovascular membranes, 238
 for choroidal nevus, 227
 for Goldmann-Favre syndrome, 188
 for retinopathy of prematurity, 285, 292, 330–333
 for sickle retinopathy, 206
- Lattice degeneration, 179, 180–182
 in myopic eyes, 391, 393
- Lawrence-Moon-Bardet-Biedl syndrome, 159, 432
 referrals and information resources regarding, 93

- Leber's congenital amaurosis, 135, 136, 155–157, 422
 animal model of, 150
 definition of, 155
 electrophysiologic findings in, 24–25, 54
 genetic loci for, 32
 macular colobomas associated with, 421
 Senior-Loken syndrome-associated, 444
- Leber's congenital neuropathy, visual evoked potentials in, 44
- Leber's hereditary optic atrophy (LHOAD), 30
- Leigh's disease, 30
- Leiomyomas, 439
- Lens
 Fabry's disease-related opacity of, 439
 thickness of, in retinopathy of prematurity, 310
- Lensectomy, as retinopathy of prematurity-related glaucoma treatment, 311
- Lenticonus
 Alport syndrome-related, 445
 anterior, 439
- Leucodystrophies
 electrophysiologic findings in, 53
 metachromatic, 53
- Leukemia, ocular manifestations of, 202, 219, 278–280
- Leukocoria, 415, 436
 medulloepithelioma-related, 276, 277
 Norrie's disease-related, 314
 parental detection of, 249, 250
 retinoblastoma-related, 249, 250, 251
 retinopathy of prematurity-related, 313, 314
- Leukovorin (folinic acid), as toxoplasmosis treatment, 359, 360–361
- Lids, colobomas of, 239
- Lid speculum, for use in premature infants, 318
- Light, as retinopathy of prematurity risk factor, 294–295
- Linear nevus sebaceous syndrome (of Jadassohn), 239
- Lipofuscin deposits
 in Best's disease, 109, 110, 111, 112, 114, 115
 drusen as, 121–124
- Lipopigment storage diseases. *See* Neuronal ceroid-lipofuscinosis
- Liver disease, retinopathy associated with, 445–446
- Low birth weight, as retinopathy of prematurity risk factor, 285–286, 289, 315
- Low vision, in children, 75–81
 clinical assessment of, 76–80
 clinical features of, 76
 incidence of, 75–76
- Low-vision aids, 76–80
 for myopic patients, 402
 for Stargardt's disease patients, 108
- Lutein, effect on macular pigmentation, 150
- Lymphocytic choriomeningitis virus (LCMV), 351, 361, 434
- Lysyl dehydrogenase deficiency, 426
- M
- Macroglobulinemia, Waldenström's, 219–220
- Macula. *See also* Maculopathy
 “black,” 449
 choroidal nevus-related lesions of, 227
 colobomas of, 414, 419–421
 ectopic, familial exudative vitreoretinopathy-related, 193
 edema of, diabetes-related, 210
 hemorrhage in, in myopic eyes, 394–396
 hyperpigmentation of, in myopic eyes, 397
 retinoblastoma-related destruction of, 249
 slowly progressive dystrophy of, 118
 tuberous sclerosis-related tumors of, 241
 underdeveloped avascular zone in, 310
- Macular degeneration, 101
 age-related, 121
 angioid streaks-related, 426

- Maculopathy
 bull's-eye, 415, 430–432
 Alström syndrome-related, 158
 cone dystrophy-related, 162
 cystoid
 Goldmann Favre syndrome-related, 36–37
 stellate, 189–190
 electrophysiologic findings in, 31–32, 40–41
 linear pigmentary, 119
- Magnetic resonance imaging (MRI), of retinoblastoma, 267–268
- Malaria, relationship with sickle cell disease, 201
- Malattia Levetinese and Doyne honeycomb retinal dystrophy, 124
- Maple syrup urine disease, 52
- Marfan syndrome, referrals and information resources regarding, 93
- Maroteaux-Lamy syndrome, 29
- Maternally inherited diabetes and deafness (MIDD), 119
- Mechanical ventilation, as retinopathy of prematurity risk factor, 294
- Medulloepitheliomas (diktyomas), 276–278
- Melanocytomas, 274–275
- Melanoma
 choroidal, 227–228, 273, 274, 275
 neurofibromatosis-related, 243
 uveal, 273–275
- Melanoma-associated retinopathy, 33
- MELAS (lactic acidosis and stroke-like episodes), 30
- Melatonin
 as color vision loss cause, 165
 as photoreceptor degeneration prophylaxis, 150
- Meningiomas, orbital, 419
- Mental retardation
 Bardet-Biedl syndrome-related, 158, 432, 442
 Norrie's disease-related, 314, 427
 referrals and information resources regarding, 93
- MERRF (myoclonic epilepsy with ragged red muscle fiber), 30
- Mesker's macreticular dystrophy, 115–116
- Metabolic disorders, cherry-red spots associated with, 414
- Metallic foreign bodies, ocular, 351, 370–381
- Metamorphopsia
 Best's disease-related, 109
 pattern dystrophy-related, 118
- Metarrhodopsin II, 6–7
- Methotrexate
 as juvenile rheumatoid arthritis treatment, 258
 as pars planitis treatment, 353
 as sympathetic ophthalmia treatment, 376
- Methoxyflurane, 129
- Michaelis-Menten equation, 7
- Microaneurysms, Takayasu's arteritis-related, 216
- Microcephaly
 lymphocytic choriomeningitis virus-related, 361
 toxoplasmosis-related, 358
- Microcornea, retinopathy of prematurity-related, 310
- Microphthalmia
 colobomatous, 419
 hypomelanosis of Ito-related, 215
 incontinentia pigmenti-related, 213
 with linear skin defects, 437
 Norrie's disease-related, 217
 retinopathy of prematurity-related, 310
 toxoplasmosis-related, 358–359
- Microphthalmos. *See* Microphthalmia
- Microvolts, 2
- Mitochondrial disease,
 electrophysiology of, 30
- Mitochondrial encephalomyopathy, 30
- Mitochondrial inheritance, of retinitis pigmentosa, 135
- Mitochondrial neurogastrointestinal encephalopathy (MNGIE), 30
- Mizuo-Nakamura phenomenon, 161
- Molecular biology, 99–100, 167
- Molecular testing, in retinitis pigmentosa patients, 148–149
- Morquio syndrome, 29
- Mucocutaneous lymph node syndrome, 220–221
- Mucopolidoses
 type I, 441–442
 type II, 441
 type III, 441
 type IV, 447

- Mucopolysaccharidoses (MPS)
 bone marrow treatment of, 448
 corneal opacities associated with, 38
 electroretinography of, 29
 visual evoked potentials in, 29
- Mueller cells, 190
- "Mulberry" lesions, 242, 243
- Müller cells, potassium ion surface conductivity in, 4–5
- Multicenter Trial of Cryotherapy for Retinopathy of Prematurity (CRYO-ROP), 285, 286–289, 294, 296, 315, 316, 320, 324–330, 331, 333
 results of, 327–329
 selection of patients for, 329–330
- Multiple myeloma, 219, 220
- Multiple sclerosis
 pars planitis-related, 353
 visual evoked potentials in, 41–42
- Mydriatic drops, 246, 248–249
- Myelination, neonatal, 24
- Myoclonic epilepsy with ragged red muscle fiber (MERRF), 30
- Myopathy, mitochondrial, 30, 429
- Myopia, 387–410
 accommodation in, 389, 400
 autosomal dominant, 399, 400
 clinical assessment of, 397–398
 clinical features of, 390–397
 fundal changes, 391–397
 vitreous changes, 390–391
 congenital stationary night blindness-related, 34, 160
 definition of, 387
 effect of ambient light on, 389–390
 etiology of, 388–390
 genetic factors in, 389–390, 399–400
 gyrate atrophy-related, 436
 high, 389, 400, 402
 complications of, 404
 unilateral, 398
 hypomelanosis of Ito-related, 215
 incidence and prevalence of, 387–388, 399
 intermediate, 388, 389
 fundus in, 391, 392–393
 intraocular pressure in, 389, 403
 lattice degeneration associated with, 391, 393
 low-vision aids for, 402
 macular colobomas associated with, 419, 420, 421
 night, 390
 overcorrection of, 397
 pathological, 389
 chorioretinal degeneration associated with, 434, 435
 fundus in, 391, 393
 treatment of, 401
 physiological (correlation), 388, 389
 fundus in, 391
 natural history of, 397–398
 in premature infants, 309
 prevention of, 400–402
 progression of, 389
 retinal complications of, 404
 retinopathy of prematurity-related, 286, 309, 312, 317, 398
 Stickler syndrome-related, 182
 systemic associations of, 398–399
 treatment of, 400, 402–405
 undercorrection of, 401, 402
- Myotonic dystrophy, 447
- N
- Naka-Rushton function, 7
- NARP (neurogenic weakness, ataxia, and retinitis pigmentosa), 30
- Necrosis, retinal
 acute, 351, 361–363
 toxoplasmosis-related, 359
- Nematodes, ocular infestations with, 351, 369–371
- Neovascularization
 choroidal, 238
 Best's disease-related, 109, 115
 histoplasmosis-related, 371, 372–373
 rubella-related, 364–365
 pars planitis-related, 353
 peripheral
 autosomal dominant
 neovascular inflammatory
 vitreoretinopathy-related, 198
 familial exudative
 vitreoretinopathy-related, 191
 pars planitis-related, 353–354
 retinal
 diabetes mellitus-related, 418
 Eales' disease-related, 213

- Neovascularization (*Continued*)
 incontinentia pigmenti-related,
 213, 214
 retinopathy of prematurity-
 related, 284, 290–292
 sickle cell disease-related, 418
 Takayasu's arteritis-related,
 216
- Neovascular membranes
 choroidal
 Amsler grid monitoring of,
 103, 120
 drusen-related, 124
 Sorsby's fundus dystrophy-
 related, 126
 treatment of, 124
 subretinal, in myopic eyes, 405
- Nephronophthisis, juvenile, 159
- Neurilemmomas, choroidal, 243
- Neuritis, optic
 pars planitis-related, 353
 toxoplasmosis-related, 359
 visual evoked potentials in,
 41–42
- Neurodegenerative disorders, visual
 evoked potentials in, 51–52, 53
- Neuroectodermal tumors, 260
- Neurofibromas, 275
 choroidal, 243
 pigmented, 274, 275
- Neurofibromatosis, 243
 referrals and information resources
 regarding, 93
- Neurogenic weakness, ataxia, and
 retinitis pigmentosa (NARP), 30
- Neuroleptics, 102
- Neurolipidosis, 29
- Neurological disorders, retinopathy
 associated with, 446–447
- Neurology, 46
- Neuromuscular disorders, retinopathy
 associated with, 446–447
- Neuronal ceroid-lipofuscinosis, 159,
 430–432, 446
 differentiated from
 Leber's congenital amaurosis,
 157
 Stargardt's disease, 108
 electrophysiologic findings in, 36,
 53
 juvenile (Batten disease), 447
 maculopathy associated with, 108
- Neurosyphilis, 366–367
- Nevi
 choroidal, 226–228, 274
 misdiagnosed as
 melanocytoma, 229
 neurofibromatosis-related, 243
- Nevus sebaceous of Jadassohn, 239
- Night blindness
 abetalipoproteinemia-related, 447
 Bardet-Biedl syndrome-related,
 27–28
 complete achromatopsia-related,
 164
 cone dystrophy-related, 162
 congenital stationary, 96, 135–136,
 139–140, 160–162
 autosomal dominant (Nougaret
 form), 160, 161
 autosomal recessive, 160, 161
 autosomal recessive
 congenital, 148
 complete, 34
 electrophysiologic findings in,
 24–25, 32–35, 51
 incomplete, 34–35
 myopia associated with, 399
 nystagmus associated with,
 155–156
 Riggs type of, 146
 Schubert-Bornschiën type of,
 146
 subtypes of, 34–35, 146
 X-linked, 32–35, 160, 161
- crystalline retinal dystrophy-
 related, 129
- erosive vitreoretinopathy-related,
 187
- Goldmann-Favre syndrome-related,
 36–37, 187
- gyrate atrophy-related, 166, 436
- retinitis pigmentosa-related,
 135–136, 137, 145, 151
- Usher syndrome-related, 437
 vitamin A deficiency-related, 378
- Night lights, as myopia risk factor,
 389–390
- Night myopia, 390
- Norrie's disease, 202, 217, 427
 differentiated from retinopathy of
 prematurity, 313, 314
 hearing loss associated with, 439
 retinal detachment associated
 with, 424, 425
- Norrie's gene mutations, 295, 424

- Norrin, 217
- North Carolina macular dystrophy, 32, 124–126, 419, 421
- NR2E3 gene mutations, 166
- Nyctalopia. *See* Night blindness
- Nystagmus
 - albinism-related, 51, 155–156
 - Alström syndrome-related, 158
 - congenital
 - achromatopsia-related, 155–156
 - albinism-related, 155–156
 - congenital stationary night blindness-related, 155–156
 - foveal hypoplasia associated with, 421
 - Leber's congenital amaurosis-related, 155–156
 - electrophysiologic findings in, 15, 31
 - infants, 54
 - hypomelanosis of Ito-related, 215
 - incontinentia pigmenti-related, 213
 - nasotemporal optokinetic, 16
 - Stickler syndrome-related, 398
 - temporonasal, 16
 - toxoplasmosis-related, 358–359
- O
- Obesity
 - Alström syndrome-related, 158
 - Bardet-Biedl syndrome-related, 158, 159, 432, 442
- Obstructive sleep apnea, 43
- Oculodigital sign of Franceschetti, 155
- Oguchi disease, 34, 161
- Olivopontocerebellar atrophy
 - type III, 430, 446, 447
 - visual evoked potentials in, 46
- Opacities, ocular, electrophysiologic findings in, 38–40
- Ophthalmia, sympathetic, 373–376
 - comparison with Vogt-Koyanagi-Harada syndrome, 378
- Ophthalmic artery occlusion, as unilateral pigmentary retinopathy cause, 165
- Ophthalmomyiasis, 351, 369–371
- Optic atrophy
 - dominant, visual evoked potentials in, 45–46
 - hereditary, visual evoked potentials in, 44–46
 - incontinentia pigmenti-related, 213
 - toxoplasmosis-related, 358–359
- Optic cup, failure of closure in, 419, 420
- Optic disc
 - coloboma of, 239
 - dilated vascular loops adjacent to, 222
 - edema of
 - carotid cavernous fistula-related, 221
 - leukemia-related, 219
 - pars planitis-related, 353
- Optic nerve
 - in albinism, 422, 423
 - choristomatous malformation of, 255
 - compression of, visual evoked potentials in, 42–44
 - drusen of, 446
 - gliomas of, electrophysiologic findings in, 44
 - granulomatous infiltration of, 354
 - hypoplasia, visual evoked potentials in, 42
 - hypoplasia of, electrophysiologic findings in, 54
 - in leukemia, 279–280
 - medulloepithelioma of, 277
- Optic nerve crescent, in myopic eyes, 391, 393
- Optic nerve head tumors
 - melanocytomas, 229–230
 - tuberous sclerosis-related, 241
- Optic pits, retinal detachment associated with, 426
- Orbit
 - angiomas of, 239
 - cellulitis of, 253
- Ornithine, as gyrate atrophy marker, 436
- Ornithine aminotransferase deficiency, 26–27, 166, 447–448
- Orthopedic abnormalities, Stickler syndrome-related, 182–184, 185
- Oscillatory potentials (OPs), 7
 - in congenital stationary night blindness, 33–34
- Osteomas, choroidal, 237–240
- Osteopetrosis, 444
 - bone marrow transplantation treatment of, 448

- Osteopetrosis (*Continued*)
 electrophysiologic findings in, 43, 54
 infantile, electrophysiologic findings in, 43
 Leber's congenital amaurosis-related, 155
- Osteoporosis, multiple myeloma-related, 220
- Osteosarcoma, 269
- Oxalosis, 449
 differentiated from crystalline retinal dystrophy, 129
- Oxygen supplementation
 as retinopathy of prematurity cause, 285, 289, 292–293
 as retinopathy of prematurity treatment, 333–334
- P
- Papilledemas, craniofacial dysostosis-related, 43
- Papillitis, incontinentia pigmenti-related, 213
- Parents
 presence during
 electrophysiological recording sessions, 21
 response to diagnosis of child's disability, 82–95
 grieving process, 86–87
 physician's role in, 88–91
 resources and referrals for, 91–95
- Pars plana, "snowbank" opacity of, 350, 352–353
- Pars planitis, 350, 351, 352–354
- Pattern dystrophies, 115–120
 benign concentric annular macular, 116, 118
 butterfly, 116, 117
 as central vision impairment cause, 103
 genetic factors in, 119–120
 Mesker's macreticular, 115–116
 peculiar foveomacular, 116, 117
 Sjögren's reticular dystrophy, 115
 treatment of, 120
- "Pavingstone" degeneration, 391
- PAX2 gene mutations, 445
- Pearson's syndrome, 30
- "Peau d'orange" fundus changes, 437, 441
- Peculiar foveomacular dystrophy, 116, 117
- Pediatric Oncology Group (POG), 257
- Pelizaeus-Merzbacher disease, 53
- Pelvis, in Stickler syndrome, 185
- Penlight technique, for iris transillumination defects diagnosis, 422
- Peripherin/RDS gene mutations, as retinitis pigmentosa cause, 137, 141, 151
- Periphlebitis, retinal, 350
- Peroxisomal disease, electrophysiology of, 27
- Persistent fetal vasculature (PFV). *See* Persistent hyperplastic primary vitreous (PHPV)
- Persistent hyperplastic primary vitreous (PHPV), 253
 differentiated from retinopathy of prematurity, 313
 histopathology of, 313
 retinal detachment associated with, 424, 426
- Peters' anomaly, 437
- Pfeifer's syndrome, 43
- Phakomatoses (neurocutaneous diseases), 202, 208–209
- Phenylephrine, 317
- Pheochromocytomas, von Hippel-Lindau syndrome-related, 208–209
- Photocoagulation
 grid, as cystoid macular edema treatment, 149
 as retinoblastoma treatment, 271
 as toxocariasis treatment, 356
- Photophobia
 Alström syndrome-related, 158
 complete achromatopsia-related, 164
- Photoreceptor disorders. *See also* Retinitis pigmentosa
 diagnosis of, 101–102
 heritable dysfunction of, 135–136
- Photosensitivity
 Alagille syndrome-related, 437
 Cockayne syndrome-related, 437
- Physician-parent interactions, 88–91
- Phytanic acid storage disease, infantile. *See* Refsum's disease, infantile
- Pierre-Robin anomaly, Stickler syndrome-related, 184

- Pigment disturbances. *See also*
Hyperpigmentation;
Hypopigmentation
differential diagnosis of, 101
geographic fundal, 434–436
“Pink eye,” misdiagnosis of, 221
Pirenzepine, 401
Plasmodium, 201
Pneumonia, *Pneumocystis carinii*, 367
“Polar bear tracks,” 232
Poliosis, Vogt-Koyanagi-Harada
syndrome-related, 376
Polycystic kidney disease, 155
Polycythemia, 219, 220
Polydactyly
Bardet-Biedl syndrome-related,
158–159, 432
retinopathy associated with, 437,
442, 443
Polyposis, intestinal, 232–234
Postchiasmal dysfunction, visual
evoked potentials in, 51–53
Posterior pole
bilateral lesions of
Best’s disease, 108–115, 148
drusen, 101, 103, 121–124,
126, 446
general approach to, 100–103
pattern dystrophies, 115–120
Stargardt’s disease, 103–108
in crystalline retinal dystrophy,
128
retinoblastomas of, 263
unilateral lesions of, 101
Prader-Willi syndrome, visual evoked
potentials in, 51
Prednisone, 216, 359, 360–361
Preeclampsia, 210, 211
Pregnancy
diabetic retinopathy during, 210
preeclampsia during, 210, 211
Premature infants
retinal vascular development in,
288
retinopathy in. *See* Retinopathy of
prematurity
Presumed ocular histoplasmosis
syndrome (POHS), 350, 351, 371–373
Prions, as ERG electrode contaminants,
9
Procollagen II gene mutations, 184
Professional kindness, in physician-
parent interactions, 90
Progeria, 444
Proparacabine, 318
Protanomaly, 163–164
Protanopia, 164
Pseudohypopyon, 267
Pseudoxanthoma elasticum, 437, 441
Ptosis, Kearns-Sayre syndrome-related,
442
Pulseless disease, 216
Pupillary block, as retinopathy of
prematurity-related glaucoma risk
factor, 310
Pupillary dilation
in retinopathy of prematurity
screening, 317–318
in well-baby examinations,
247–249
Pupillary red-reflex examination, 247
Pupils, size of, effect on
electroretinogram, 10
Pyramethamine, as toxoplasmosis
treatment, 359, 360–361
- R
Radiotherapy, intensity-modulated, as
retinoblastoma treatment, 273
Rb gene mutations, 270
Rb-1 gene product, in retinoblastoma,
258–259
RDS/peripherin gene mutations, 119-
120. *See also* Peripherin/RDS gene
mutations
Reese-Ellsworth (R-E) classification, of
retinoblastoma, 261
Refraction, cycloplegic, for myopia
assessment, 397
Refractive errors
effect on electroretinograms, 10
in myopic eyes, 389
retinopathy of prematurity-related,
153–154
retinopathy of prematurity-related,
309–310
Refractive surgery, for myopia
correction, 403
Refsum’s disease, 436, 437
flash electroretinograms in, 27
infantile, 157, 441, 444, 446, 447
treatment of, 448
Renal cell carcinoma, 208–209
Renal-coloboma syndrome, 445
Renal disease, retinal disorders
associated with, 437, 444–445

- Renal failure
 Alström syndrome-related, 158
 retinitis pigmentosa-related, 159
- Renal stones, 444, 449
- Respiratory insufficiency, chronic, 419
- Retina
 combined hamartomas of, 235–237
 magnocellular projecting system of, 15
 parvocellular projecting system of, 15
 response to light, 4–5
 retinitis pigmentosa-related
 degeneration of, 153
 tears of, in myopic eyes, 391, 393, 404
 vascular development in
 hypoxia-related impairment of, 289–293
 in premature infants, 288
 vascular disorders of, 201–225
 anemia, 202, 218
 carotid cavernous fistula, 202, 221
 Churg-Strauss syndrome, 202, 216
 Coats' disease, 202, 206–208
 congenital vascular loops, 202, 222–223
 diabetic retinopathy, 202, 210
 Eales' disease, 202, 213
 fascioscapulohumeral dystrophy, 202, 217–218
 Goodpasture's syndrome, 202, 215–216
 hypertensive retinopathy, 202, 210–211
 hyperviscosity syndromes, 202, 219–220
 hypomelanosis of Ito, 202, 215
 incontinentia pigmenti, 202, 213–215
 Kawasaki's disease, 202, 220–221
 leukemia, 202, 219
 Norrie's disease, 202, 217
 phakomatoses (neurocutaneous diseases), 202, 208–209
 Purtscher's retinopathy, 202, 212–213
 shaken baby syndrome, 202, 212
 sickle cell disease, 201, 203–206
 Takayasu's arteritis, 202, 216
 Terson's syndrome, 202, 211–212
 treatment of, 449
 vein occlusions, 202, 222
- Retinal artery occlusion, cherry-red spots associated with, 416
- Retinal degeneration, Usher syndrome-related, 157
- Retinal detachment, 414, 424–426
 acute retinal necrosis-related, 363
 autosomal dominant neovascular inflammatory vitreoretinopathy-related, 198
 choroidal osteoma-related, 237
 Coats' disease-related, 207–208
 Ehlers-Danos VI syndrome-related, 426
 erosive vitreoretinopathy-related, 186
 familial exudative vitreoretinopathy-related, 191, 193, 194
 Goodpasture's syndrome-related, 215
 hypertensive retinopathy-related, 210
 hypomelanosis of Ito-related, 215
 lattice degeneration-related, 180–182
 leukemia-related, 279
 in myopic eyes, 389, 391, 403, 404–405
 Norrie's disease-related, 424, 425
 optic nerve pits-related, 426
 pars planitis-related, 353
 persistent hyperplastic primary vitreous (PHPV)-related, 424, 426
 retinal dysplasia-related, 424
 retinoblastoma-related, 263
 retinopathy of prematurity-related, 284, 286, 287–288, 289, 297, 299, 301, 302, 424
 differentiated from
 retinoblastoma, 313–314
 early stages of, 304–305
 late-onset, 312
 subtotal, 306, 307
 total, 306–309
 treatment of, 312, 334–337

- Retinal detachment (*Continued*)
 vitreoretinal traction forces in,
 307–309
 spondyloepiphyseal dysplasia
 congenita-related, 426
 Stickler syndrome-related, 182,
 186, 424, 426
 Sturge-Weber syndrome-related, 209
 Takayasu's arteritis-related, 216
 toxocariasis-related, 356
 toxoplasmosis-related, 359
 trauma-related, 424
 tumor-related, 424
 uveal melanoma-related, 275
 X-linked juvenile retinoschisis-
 related, 426
- Retinal pigment epithelial leakage, 139
- Retinal pigment epithelium (RPE)
 basement membrane abnormalities
 of
 drusen-related, 121, 122, 123,
 124
 North Carolina macular
 dystrophy-related, 125
 combined hamartomas of, 235–237
 congenital hyperplasia of, 234–235
 congenital hypertrophy of, 230–232
 inherited gastrointestinal
 polyposis associated with,
 232–234
 in erosive vitreoretinopathy, 186
 in fenestrated sheen macular
 dystrophy, 128
 hamartomas of, 274
 lymphocytic choriomeningitis
 virus-related migration of, 371
 myopia-related tessellation of, 391,
 392, 393
 myopia-related thinning of, 391
 North Carolina macular dystrophy-
 related, 125
 "salt-and-pepper" fundus
 associated with, 427–428
 toxoplasmosis-related disruption
 of, 359
 in Wagner's disease, 186
- Retinal-renal syndromes, 159
- Retinitis
 congenital syphilis-related, 429
 cytomegalovirus-related, 367–369,
 434
 necrotizing, 361, 362–363
 toxoplasmosis-related, 359
- Retinitis pigmentosa, 135–177
 autosomal dominant, 135,
 136–137, 140–141, 150–152
 electroretinography of, 26
 molecular biology-based
 diagnosis of, 167
 autosomal recessive, 135, 140–141,
 152–153
 Bothnia-type, 152–153
 prognosis for, 26
 a-wave amplitude in, 7
 as blindness cause, 141
 carriers of, 154
 clinical features of, 137–141
 Darier's disease-related, 436, 437
 dark adaptometric evaluation of,
 141, 145
 definition of, 135
 digenic, 154–155
 electroretinographic findings in,
 24–25, 145–148
 fundus abnormalities in, 137, 138,
 139–140
 hereditary, 150–154
 Leber's congenital amaurosis as,
 135, 136
 molecular testing in, 148–149
 myopia-associated, 399
 prevalence of, 135
 rhodopsin-associated, 140
 denaturing gradient gel
 analysis of, 152
 electroretinography of, 147
 genetic factors in, 151, 152
 visual field loss in, 143, 144
 rod dysfunction associated with, 25
 scotomas associated with, 141, 142
 systemic diseases associated with,
 157–159
 treatment of, 149–150
 unilateral, 165
 vitamin A treatment of, 449
 workup of, 141–149
 X-linked, 135
 carriers of, 26
 electroretinography of, 26
 genetic factors in, 155
 recessive, 146, 151, 153–154
- Retinitis pigmentosa sine pigmento,
 137–138, 140–141
- Retinitis punctata albescens, 139,
 140–141
 RLBP1 gene mutations-related, 153

- Retinoblastoma, 246–273
- astrocytic hamartoma
 - misdiagnosed as, 241–242
 - atypical, 251–253
 - “bay complex” and, 272
 - bilateral, 251, 259, 260, 269, 313
 - misdiagnosis of, 272–273
 - clinical presentation of, 249–257, 261–269
 - natural history, 261–267
 - natural history of, 261–267
 - workup in, 267–269
 - differentiated from
 - leukocoria, 436
 - retinopathy of prematurity, 313, 314
 - diffuse infiltrating, 267
 - early detection of, 246–249
 - endophytic, 252, 263, 268
 - epidemiology of, 254, 256, 257
 - etiology of, 258–260
 - extraocular, 262
 - “gene carriers” of, 259
 - genetic counseling for, 270, 271
 - genetic factors in, 258, 259–260, 270
 - chromosomal 13q14 deletion, 259, 260
 - incidence of, 247, 254
 - metastatic, 252
 - as bone tumor cause, 268, 269
 - histopathological risk factors for, 270–271
 - staging of, 261
 - treatment of, 271, 273
 - as multiple lesions, 261, 263
 - nongenetic form of, 258–259
 - prevalence of, 254, 256
 - screening for, 246–249, 251
 - staging of, 261
 - treatment of, 271–273
 - undiagnosed, 252
 - unilateral, 313
 - untreated, 263
 - vitreous seeding by, 263, 266, 267
- Retinochoroiditis, toxoplasmosis-related, 358
- Retinocytomas, 264–265
- Retinomas, 261, 264–265
- Retinopathy
- anemic, 218
 - central serous, 41
 - diabetic, 202, 210
 - fundal patterns in, 413–436
 - angioid streaks, 415, 426–427
 - bull’s-eye maculopathy, 415, 430–432
 - cherry-red spots, 413, 414, 416
 - congenital retinal disease, 415, 432–434
 - foveal hypoplasia, 414, 421–424
 - “fried-egg” appearance, 31–32
 - geographic pigmentary disturbances, 415, 434–436
 - leukocoria, 415, 436
 - macular colobomas, 414, 419–421
 - “peau d’orange” appearance, 437, 441
 - retinal detachment, 414, 424–426
 - “salt-and-pepper” mottling, 363–364, 365, 366, 415, 427–429
 - “scrambled-egg” appearance, 32
 - vascular tortuosity, 414, 416–419
 - vitreoretinal dysplasia or aplasia, 415, 427
 - hypertensive, 202, 210–211
 - leukemic, 278–279
 - pigmentary
 - Bardet-Biedl syndrome-related, 27–28
 - neuronal ceroid-lipofuscinosis-related, 430
 - unilateral, 165
 - Usher syndrome-related, 28
 - Purtscher’s, 202, 212–213
 - rubella, 363–365
 - sickle, 201, 203–206
 - systemic disorders associated with, 436–449
- Retinopathy of prematurity, 284–349
- as blindness cause, 285, 286
 - cryotherapy for, 323–330
 - CRYO-ROP study of, 324–330, 331, 333
 - as myopia risk factor, 398
 - techniques in, 324–327
 - definition of, 284
 - demarcation line in, 296, 303, 304, 397, 398
 - as double line, 317

- Retinopathy of prematurity
 (*Continued*)
 differential diagnosis of, 313–314
 early detection of, 246
 in full-term infants, 314
 incidence of, 285–286
 International Classification of Retinopathy of Prematurity (ICROP) for, 295–302, 316
 extent (“clock hours”)
 parameter of, 295, 296, 299
 location zone parameter of, 295–296
 severity (stages) parameter of, 295, 296–302, 303–309, 418–419
 myopia associated with, 398
 natural history of, 285–286
 as neovascularization cause, 284
 ischemia-related, 284, 290–292
 Norrie’s gene mutations associated with, 424
 pathogenesis of, 289–295
 oxygen in, 290–293
 risk factors, 293–295
 vascular endothelial growth factor in, 290–292
 prethreshold, 287, 288, 294
 examination of, 316–317
 oxygen therapy for, 333–334
 parental notification about, 319
 progression of, 284, 286
 prophylaxis and treatment of, 319–322
 regressed, 301, 302
 late complications of, 310–312
 ocular findings in, 309–310
 reactivation of, 317
 retinal detachment associated with, 284, 286, 287–288, 289, 297, 299, 301, 302, 424
 differentiated from
 retinoblastoma, 313–314
 early stages of, 304–305
 late-onset, 312
 subtotal, 306, 307
 total, 306–309
 treatment of, 312, 334–337
 vitreoretinal traction forces in, 307–309
 retinal vascular tortuosity
 associated with, 418–419
 as retrolental fibroplasia, 284–285
 ridge in, 296, 297, 298–300, 304–305
 with extraretinal fibrovascular proliferation, 297, 303–306
 screening for
 follow-up schedule in, 316–317
 mode of examination in, 317–319
 selection of patients for, 314–317
 severity (stages) of, 295, 296–302
 clinicopathological correlation of, 303–309
 “plus” stage, 288, 292, 294, 299, 300, 418–419
 stage 1, 288, 291, 292, 296, 297, 303, 304
 stage 2, 288, 291, 292, 296, 297, 298, 303, 305
 stage 3, 292, 297, 298–299, 303–306
 stage 4, 292, 297, 299, 306, 307, 334–335
 stage 4A, 301
 stage 5, 292, 297, 299, 301, 306–309
 spontaneous regression of, 284, 286
 threshold, 287–288, 289
 cryotherapy for, 324–330
 laser photocoagulation therapy for, 330–333
 screening for, 314
 treatment of, 285, 319–322
 as vascular shunt cause, 284
 ischemia-related, 284, 291, 292
 in retinal detachment, 306–307
 vitreoretinal surgical treatment of, 335–337
- Retinopathy patients, physical examination of, 412
- Retinoschisis
 foveal, 166
 Goldmann-Favre syndrome-related, 187, 188
 X-linked, 179, 189–191, 237
 electrophysiological findings in, 35
 histopathology of, 35
 juvenile, 166, 426
- Rheumatoid arthritis, juvenile, 351, 357–358
- Rhinitis, congenital syphilis-related, 429

- Rhodopsin, lifetime of, in rods, 5
 Rhodopsin gene mutations, 137, 151
 RLBP1 gene mutations, 152–153
 Rod/cone dystrophies
 Bardet-Biedl syndrome-related, 158
 progressive. *See* Retinitis pigmentosa
 Rod dysfunction
 electroretinography of, 25–26
 gyrate atrophy-related, 26–27
 Rodents, as lymphocytic choriomeningitis virus hosts, 361
 Rod monochromatism, 164
 electrophysiologic findings in, 30–31
 Rods, electroretinography of, 4, 6, 8, 22, 23
 ROP. *See* Retinopathy of prematurity
 Roundworm infestations. *See* Toxocariasis
 RP. *See* Retinitis pigmentosa
 RPE. *See* Retinal pigment epithelium (RPE)
 RPGR gene mutations, 26
 retinitis pigmentosa-associated, 154
 Rubella, 351, 363–365, 432–433, 439
 as “salt-and-pepper” fundus cause, 428–429
 Rubeosis, medulloepithelioma-related, 276
 Rubeosis iridis, 213, 292
 “Rust spots,” siderosis-related, 379, 380, 381
- S
- “Sabre shins,” syphilis-related, 365
 “Saddle nose,” syphilis-related, 365
 Saethre Chotzen syndrome, 43
 Saldino-Mainzer syndrome, 159
 Sarcoidosis, 351, 354–355
 Scapuloperoneal dystrophy, 218
 Sclerae, blue, incontinentia pigmenti-related, 213
 Scleral buckling procedures, 312
 in myopic eyes, 402
 as retinal detachment treatment
 in familial exudative vitreoretinopathy, 194
 in retinopathy of prematurity, 334–335
 technique of, 334–335
 Scleral shortening, in myopic eyes, 401
- Scoliosis, Kniest dysplasia-related, 399
 S-cone syndrome, enhanced, 36–37, 166
 Scotomas
 paracentral, retinitis pigmentosa-related, 141
 ring
 cone dystrophy-related, 162
 retinitis pigmentosa-related, 141, 142
 visual evoked potentials in, 18
 Scotopic threshold response (STR), 8
 Sea fans, 204, 205, 206
 Sedation, during electroretinography, 21
 Seizures
 hypomelanosis of Ito-related, 215
 neuronal ceroid-lipofuscinosis-related, 430
 toxoplasmosis-related, 358
 tuberous sclerosis-related, 241
 Zellweger’s syndrome-related, 447
 Senior-Loken syndrome, 159, 444
 Sepsis, as retinopathy of prematurity risk factor, 293, 294
 Sexual abuse, of children, 213
 Shaken baby syndrome, 202, 212
 Sheie syndrome, 29
 Short stature, 437, 442, 444
 infantile osteopetrosis-related, 43
 Shunts, vascular
 arteriovenous, 221
 retinopathy of prematurity-related, 284, 291, 292, 306–307
 Sick cell disease, 201, 203–206
 bone marrow transplantation treatment of, 448
 branch retinal vein occlusions associated with, 222
 retinal neovascularization associated with, 418
 Sickle disc sign, 204
 Siderosis, 351, 379–381
 Sjögren-Larsson syndrome, 102, 436, 437
 Sjögren’s reticular dystrophy, 115
 Skeletal anomalies, retinopathy associated with, 437, 444
 Sloan achromatopsia test, 164
 “Snowballing,” vitreous
 pars planitis-related, 350
 sarcoidosis-related, 354
 “Snowbanking,” pars planitis-related, 350, 352–353

- "Snowflakes," hereditary vitreoretinal degeneration of Hirose-related, 194–196
 Sorsby's fundus dystrophy, 126–127
 Speech impairment, Usher syndrome-related, 157
 Spielmeyer-Batten-Vogt syndrome, 159
 Spinocerebellar ataxia type 7, 167
 Spinocerebellar atrophy 6, 430, 446–447
 Spondyloepiphyseal dysplasia, 442, 444
 Spondyloepiphyseal dysplasia congenita, 399, 426
 Staphylomas, 393–394
 North Carolina macular dystrophy-related, 124–125
 surgical treatment of, 400
 Stargardt's disease, 26, 103–108, 430
 age distribution of, 107
 autosomal dominant inheritance of, 107–108
 autosomal recessive inheritance of, 107–108
 central vision impairment associated with, 103, 107
 differentiated from cone-rod dystrophies, 108, 162
 early-onset
 differentiated from pattern dystrophies, 118–119
 masked choroid associated with, 104, 118
 electrophysiologic findings in, 32
 maculopathy associated with, 104, 105, 107
 natural history of, 103–107
 pathophysiology of, 108
 Stickler syndrome, 179, 182–186
 electroretinographic findings in, 37
 genetic factors in, 37, 182, 184
 management of, 184, 186
 myopia associated with, 398, 399
 retinal detachment associated with, 424, 426
 systemic manifestations of, 182–184, 185
 STOP-ROP trial, 333–334
 Storage diseases, cherry-red spots associated with, 414
 Strabismus
 Coats' disease-related, 206
 cortical visual acuity suppression associated with, 58–59
 hypomelanosis of Ito-related, 215
 incontinentia pigmenti-related, 213
 Leber's congenital amaurosis-related, 155
 retinoblastoma-related, 250, 251
 retinopathy of prematurity-related, 286, 309–310, 317
 toxocariasis-related, 355
 toxoplasmosis-related, 358–359
 Sturge-Weber syndrome, 208, 209
 Styrene, as color vision loss cause, 165
 Sulfadiazine, as toxoplasmosis treatment, 359, 360–361
 Surfactant therapy, as retinopathy of prematurity prophylaxis, 320
 Syndactyly, Bardet-Biedl syndrome-related, 158–159
 Synechiae
 juvenile rheumatoid arthritis-related, 357, 358
 as retinopathy of prematurity-related glaucoma risk factor, 311
 Syphilis, 351, 365–367
 acquired, 365
 treatment of, 366–367
 congenital, 429, 433
 prevention of, 365
 treatment of, 365–366, 433–434
 ocular manifestations of, 365–367
 treatment of, 433–434, 448–449

T
 Takayasu's arteritis, 202, 216
 Talc exposure, toxicity of, 129, 351
 Tamoxifen, toxicity of, 102, 129, 351
 Tay-Sachs disease
 cherry-red spots associated with, 413, 414
 electrophysiologic findings in, 53
 Telangiectasia, retinal
 Coats' disease-related, 206, 207, 217–218, 417
 fascioscapulohumeral dystrophy-related, 217–218
 scapuloperoneal dystrophy-related, 218
 Terson's syndrome, 202, 211–212
 TFSOM (To Find Small Ocular Melanoma) mnemonic, 228
 Thiabendazole, 356
 Thioridazine, toxicity of, 25, 351
 Thrombocytopenia, anemia-related, 218

- Tibia, Stickler syndrome-related dysplasia of, 183–184, 185
- Timolol maleate eye drops, 401
- Tinnitus, Vogt-Koyanagi-Harada syndrome-related, 376
- Tocopherols, 321
- Toe-to-heel walking, in Usher syndrome patients, 158
- TORCH infections, 165, 361, 432
- Tortuosity, vascular, 414, 416–419
 - familial retinal arteriolar, 416–417
 - in retinoblastoma, 263
- Toxic diseases
 - differentiated from inherited disease, 102
 - drug toxicities
 - canthaxanthine, 129, 351
 - electrophysiologic findings in, 46–47
 - tamoxifen, 102, 129, 351
 - thioridazine, 25, 351
 - flash electroretinogram in, 24–25
 - of the retina and vitreous, 351
- Toxocara canis*, 355
- Toxocara cati*, 355
- Toxocariasis, ocular, 351, 355–357
- Toxoplasma gondii*, as toxoplasmosis cause, 358, 359
- Toxoplasmosis, ocular, 351, 358–361
 - congenital, 432
 - macular colobomas associated with, 419, 421
 - treatment of, 359, 433–434
 - differentiated from
 - ocular toxocariasis, 356–357
 - retinoblastoma, 255
 - “headlight-in-the-fog” appearance of, 359, 360
 - prevention of, 361
 - treatment of, 359–361
- Trauma
 - as sympathetic ophthalmia cause, 373–374
 - as unilateral pigmentary retinopathy cause, 165
- Treponema pallidum*, as syphilis cause, 365
- Trichomats, 163
- Trisomy 13, 427
- Trisomy 21 (Down syndrome), 427
- Tritanomaly, 163–164
- Tropicamide, 317
- Trust, in physician-parent interactions, 89
- Truth, in physician-parent interactions, 88
- Tuberous sclerosis, 241–243
 - astrocytic hamartomas associated with, 254
- Tumor necrosis factor- α , 358
- Tumors
 - malignant intraocular, 246–283. *See also* Retinoblastoma
 - leukemia, 278–280
 - medulloepithelioma (diktyoma), 276–278
 - uveal melanoma, 273–275
 - pigmented intraocular, differential diagnosis of, 274–275
- Turcot’s syndrome, 232
- U
- Unilateral occipital hemisphere dysfunction, 53
- Unilateral pigmentary retinopathy, 165
- Usher syndrome, 139, 157–158, 437
 - genetic factors in, 153
 - macular pigmentation in, 150
 - subtypes of, 28, 157, 158
- Uvea
 - melanocytoma of, 229, 230
 - melanoma of, 273–275
- Uveitis
 - congenital syphilis-related, 429
 - juvenile rheumatoid arthritis-related, 357–358
 - Kawasaki’s disease-related, 220–221
 - sarcoidosis-related, 354, 355
 - sympathetic ophthalmia-related, 373–376
 - syphilis-related, 367
 - toxoplasmosis-related, 358–359, 360
- Uvula, bifid, Stickler syndrome-related, 184, 398–399
- V
- Valganciclovir, as cytomegalovirus retinitis treatment, 369
- Varicella virus, 433
- Vascular disorders, retinal, 201–225
 - anemia, 202, 218
 - carotid cavernous fistula, 202, 221
 - Churg-Strauss syndromes, 202, 216

- Vascular disorders, retinal (*Continued*)
- Coats' disease, 202, 206–208
 - congenital vascular loops, 202, 222–223
 - diabetic retinopathy, 202, 210
 - Eales' disease, 202, 213
 - fascioscapulohumeral dystrophy, 202, 217–218
 - Goodpasture's syndrome, 202, 215–216
 - hypertensive retinopathy, 202, 210–211
 - hyperviscosity syndromes, 202, 219–220
 - hypomelanosis of Ito, 202, 215
 - incontinentia pigmenti, 202, 213–215
 - Kawasaki's disease, 202, 220–221
 - leukemia, 202, 219
 - Norrie's disease, 202, 217
 - phakomatoses (neurocutaneous diseases), 202, 208–209
 - Purtscher's retinopathy, 202, 212–213
 - shaken baby syndrome, 202, 212
 - sickle cell disease, 201, 203–206
 - Takayasu's arteritis, 202, 216
 - Terson's syndrome, 202, 211–212
 - treatment of, 449
 - vein occlusions, 202, 222
- Vascular endothelial growth factor (VEGF), 290–292, 333
- Vascular loops
- congenital, 202, 222–223
 - peripapillary, anomalous retinal blood vessels in, 416–417
 - retinal venous
 - branch retinal vein occlusions associated with, 222
- Vascular tortuosity, 414, 416–419
- Vasculature, retinal
- development of
 - hypoxia-related impairment of, 289–293
 - in premature infants, 288
 - in familial exudative vitreoretinopathy, 191, 194
 - tortuosity of, 414, 416–419
 - familial retinal arteriolar, 416–417
 - retinoblastoma-related, 263
- Vein occlusions, retinal, 202, 222
- branch, 222–223
 - hyperviscosity syndromes-related, 222
 - sarcoidosis-related, 354
- Venereal Disease Research Laboratory (VDRL) test, for syphilis, 365
- Vernier acuity, 16
- Very-low birth weight infants
- pupillary dilation in, 317–318
 - retinopathy of prematurity in, 286–289, 292–293
 - prevention of, 320
- Vestibular abnormalities, Usher syndrome-related, 157, 158, 437
- Vigabatrin
- as color vision loss cause, 165
 - visual electrophysiologic effects of, 46
- Vinblastin, visual electrophysiologic effects of, 47
- Vincristine, 271, 272
- visual electrophysiologic effects of, 47
- Visceral larva migrans, 355–356
- Visual acuity impairment
- Best's disease-related, 109, 110
 - Coat disease-related, 207, 208
 - Goldmann-Favre syndrome-related, 188
 - myopia-related, 393–394, 400
 - pattern dystrophy-related, 118
 - retinitis pigmentosa-related, 149
 - Stargardt's disease-related, 103, 105, 106
 - X-linked juvenile retinoschisis-related, 190
- Visual acuity testing, visual evoked potentials in, 54–59
- in amblyopia, 54–56
 - in hysterical (or functional) visual loss, 58
 - in strabismus, 58–59
 - sweep VEPs, 56–59
- Visual evoked potentials (VEPs), 13–19
- amplification of, 10–11
 - in combination with
 - electroretinography, 2, 21–23
 - GOS pediatric protocol for, 21–23
 - cortical origins of, 13–16
 - definition of, 1
 - in delayed visual maturation, 156
 - diagnostic applications of, 38–53

Visual evoked potentials (VEPs)

(Continued)

EEG electrode-based recording of, 9
 electrodes for, transoccipital
 montage of, 19

flash, 14

in cortical blindness, 51–52
 cortical origins of, 13–14
 in Goldmann Favre syndrome,
 36–37

in neuronal ceroid-
 lipofuscinosis, 36

in optic nerve hypoplasia, 42
 in postchiasmal dysfunction,
 52, 53

in unilateral occipital
 hemisphere dysfunction, 53

in Leber's congenital amaurosis,
 25

magnocellular projecting system
 and, 15

maturation of, 24

motion processing-related, 15–16

multifocal, 13

in optic nerve disorders, 41–44
 half-field testing of, 41

parvocellular projecting system
 and, 15

pattern, 2

in Bardet-Biedl syndrome, 28

chloral hydrate, 55

in congenital hereditary
 endothelial dystrophy
 (CHED), 39, 40

in lens opacity, 39

in optic nerve compression,
 42–44

in optic nerve hypoplasia, 42

pattern-onset, 13, 15

cortical origins of, 14

development of, 24

pattern-reversal, 14

in cerebellar ataxia, 45–46

in hereditary optic atrophy,
 44–46

macular and paramacular,
 17–18

in maculopathies, 40–41

in optic neuritis, 41–42

paradoxical localization of,
 16–17

in postchiasmal dysfunction,
 51–52

in unilateral occipital
 hemisphere dysfunction, 53

in visual acuity testing, 54,
 55–56, 58–59

recording techniques for, 13

in children, 18–19

in rod dysfunction, 25

signal averaging of, 11

steady-state, 13

sweep, 13

transient, 13

vernier, 16

in visual acuity testing, 54–59

in amblyopia, 54–56

in hysterical (or functional)
 visual loss, 59

in strabismus, 58–59

sweep VEPs, 56–57

Visual field loss, retinitis pigmentosa-
 related, 141, 143, 144

Visual fields, Usher syndrome-related
 abnormalities of, 158

Visual loss/impairment

acute retinal necrosis-related, 363

hysterical, visual evoked potentials
 in, 58

myopia-related, 394–396

pars planitis-related, 353

referrals and information resources
 regarding, 93–94

Visual maturation, delayed

differentiated from Leber's
 congenital amaurosis, 156
 electrophysiology of, 24

Vitamin A, therapeutic applications of,
 127, 448, 449

Vitamin A deficiency, 378–379, 449,
 3351

as retinitis pigmentosa mimic,
 149–150

rod dysfunction associated with,
 25

Vitamin A palmitate, 150

Vitamin B₆, as gyrate atrophy
 treatment, 27

Vitamin B₁₂ deficiency, visual
 electrophysiologic effects of, 47

Vitamin E, therapeutic applications of,
 46, 285, 320–322, 448

Vitamin E deficiency

rod dysfunction associated with, 25
 visual electrophysiologic effects of,
 47–48

- Vitamin K, therapeutic applications of, 448
- Vitelliform dystrophy, Best's. *See* Best's dystrophy
- Vitelliform lesions
- peculiar foveomacular dystrophy-related, 117
 - of the posterior pole, 101
- Vitiligo, 376, 437
- Vitreotomy, 253
- as advanced retinopathy of prematurity treatment, 335–337
 - as ocular toxocariasis treatment, 356
 - pars plana*, 353–354
 - as retinopathy of prematurity-related retinal detachment treatment, 312
 - as retinopathy of prematurity-related glaucoma treatment, 311
- Vitreitis, *pars planitis*-related, 353–354
- Vitreoretinal traction bands, 355
- retinopathy of prematurity-related, 312
- Vitreoretinopathies, 178–200, 391
- autosomal dominant neovascular inflammatory vitreoretinopathy, 179, 197–198
 - autosomal dominant vitreoretinopathopathy, 179, 196–198
 - electrophysiologic findings in, 36–37
 - erosive vitreoretinopathy, 179, 186–187
 - familial exudative (FEVR), 179, 191–194, 313, 314, 424
 - Goldmann-Favre syndrome, 179, 187–188
 - hereditary snowflake vitreoretinal degeneration of Hirose, 179, 194–196
 - lattice degeneration, 179, 180–182
 - Stickler syndrome, 179, 182–186
 - Wagner syndrome, 179, 186–187
 - X-linked retinoschisis, 179, 189–191
 - in myopic eyes, 390–391
 - pars planitis*, 350, 351, 352–354
 - “snowball” opacity of, 350
 - in Stickler syndrome, 182
- Vitreous body, in retinopathy of prematurity, 306
- Vitreous detachment
- autosomal dominant vitreoretinopathopathy-related, 196–197
 - in myopic eyes, 390, 404
- Vitreous haze, toxoplasmosis-related, 350, 360
- Vitreous syneresis, in myopic eyes, 390–391
- Vitreous traction, Wagner disease-related, 186–187
- Vitritis, acute retinal necrosis-related, 361
- VMD2 gene mutations, 111, 112
- Vogt-Koyanagi-Harada syndrome, 376–378, 437
- Vogt's ring, 391
- von Hippel-Lindau syndrome, 208–209
- capillary hemangiomas associated with, 417
- W
- Waardenburg's syndrome, 442
- Wagner's vitreoretinal degeneration, 37
- Wagner syndrome, 179, 186–187
- Waldenström's macroglobulinemia, 219–220
- Warburg syndrome, 427
- “White-dot” syndromes, 355, 371
- Wills Eye Institute, 273–274
- Wilms' tumor, 424
- Wyburn-Mason syndrome, 208, 209
- X
- Xanthine, as retinopathy of prematurity risk factor, 294
- Xanthogranulomas, juvenile, 274, 277
- Xerophthalmia, vitamin A deficiency-related, 378
- X-linked inheritance, of retinitis pigmentosa, 135
- XLRS1 gene mutations, 166
- Z
- Zellweger's syndrome, 27, 446, 447
- Zolof, as color vision loss cause, 165